Christoph Pohl - Concepedia

Author

Christoph Pohl

Heinrich Heine University Düsseldorf ORCID

Also Known As

C J Pohl, C POHL, C Pohl, C. POHL, C. Pohl, C. Pohl*, CHRISTOPH POHL, Christoph Pohl, L Bauer, Mario Ghazi

250

Publications

9.9K

Citations

H-Index

220

Concepts

All Affiliations

Heinrich Heine University Düsseldorf University Hospital Bonn Bayer (Germany)University of Bonn University of Cologne

About

Christoph Pohl is an author at Heinrich Heine University Düsseldorf specializing in medicine, immunology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	37	4.3K
2	Engineering	13	15	690
3	Health Sciences	6	6	251
4	Education	1	1	13
5	Management	1	1	117

Christoph Pohl

116

Publications

Citations

H-Index

Page 1

	Year	Citations
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Ludwig Kappos, Chris H. Polman, Mark S. Freedman, American Journal of Ophthalmology Autoimmune DiseaseMcdonald MsImmunodeficienciesImmunologyMultiple Sclerosis	2006	551
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression Alberto Ascherio, Kassandra L. Munger, Rick White, JAMA Neurology	2014	503
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Ludwig Kappos, Mark S. Freedman, Chris H. Polman, The Lancet Disease ProgressionNeurological DisorderClinical TrialsBenefit StudyBeta-1b Treatment	2007	499
Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study Heyder Omran, Harald Schmidt, M. H. Hackenbroch, The Lancet Aortic ValveEndovascular TechniqueValvular StenosisVascular SurgeryValve Disease	2003	416
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, The Lancet Neurology Relapsing-remitting Multiple SclerosisNeurological DisorderMulticentre StudyImmunologyClinical Trials	2009	402
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Ludwig Kappos, Mark S. Freedman, Chris H. Polman, The Lancet Neurology Disease ProgressionImmunologyClinical TrialsClinical NeurologyNeurological Progress	2009	367
Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule Andreas Hombach, Anja Wieczarkowiecz, Thomas Marquardt, The Journal of Immunology	2001	290
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score Philip L. De Jager, Lori B. Chibnik, Jing Cui, The Lancet Neurology Disease SusceptibilityClinical AlgorithmMedicinePolygenic RiskGenetic Epidemiology	2009	264
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis Jens Kühle, Christoph Pohl, Matthias Mehling, New England Journal of Medicine	2007	257
Chronic inflammatory bowel disease and cancer. Christoph Pohl, Andreas Hombach, W Kruis PubMed InflammationChronic Inflammatory DiseasesHepatologyGastrointestinal OncologyMedicine	2000	165

Page 1